Drugs / Sacituzumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06204614 | Jun 2024 → Jul 2028 expected | infiltrating bladder urothelial carcinoma | Brigham and Women's Hospital | Enrolling by invitation | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06040970 | Oct 2024 → Jul 2026 overdue | ovarian cancer, uterine cancer | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacituzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06040970 ↗ |
| Known as | HRS7 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3707405 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3707405 ↗ |
| Route | Intravenous | “Sacituzumab govitecan 5-7.5 mg/kg IV (depending on phase I result)” NCT06040970 ↗ |